First Data on GLP-1 Agonist/SGLT2 Inhibitor Combo in Diabetes First Data on GLP-1 Agonist/SGLT2 Inhibitor Combo in Diabetes
Exenatide once weekly combined with daily dapagliflozin improved glycemic outcomes, BP, and weight loss more than each drug alone in DURATION-8, the first trial to examine a combination of these 2 agents.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
More News: Byetta | Dapagliflozin | Diabetes | Endocrinology | Forxiga | SGLT2 Inhibitors | Weight Loss